Donepezil oral dispersible film - APR Applied Pharma Research/Labtec

Drug Profile

Donepezil oral dispersible film - APR Applied Pharma Research/Labtec

Alternative Names: Donepezil ODF

Latest Information Update: 19 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator APR Applied Pharma Research; Labtec
  • Developer APR Applied Pharma Research; tesa Labtec
  • Class Antidementias; Indans; Nootropics; Piperidines; Small molecules
  • Mechanism of Action Acetylcholinesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Alzheimer's disease

Most Recent Events

  • 19 Sep 2017 Discontinued - Registered for Alzheimer's disease in Portugal, Spain and Germany (PO) before September 2017, because Labtec dropped the approval for the product in Europe (Email communication with tesa Labtec GmbH, September 2017)
  • 15 Mar 2016 Biomarkers information updated
  • 05 Oct 2010 Donepezil ODF licensed to Ferrer in Spain, Portugal and Germany
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top